Health Care·Life Sciences Tools & Services·$7.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.91 | N/A | +136.59% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.91 | N/A | +136.59% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed confidence in their strategic direction despite not providing specific guidance. They emphasized the importance of continued innovation.
Management highlighted strong performance in key segments.
They noted ongoing investments in innovation and product development.
Bio Rad Laboratories reported a strong earnings surprise with an EPS of $0.91, significantly exceeding expectations. However, the stock reacted negatively, declining by 0.42%. This may indicate investor caution despite the positive earnings performance, as there was no revenue data or future guidance provided.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ROPER TECHNOLOGIES I
Oct 30, 2017